Oncology Consortium

Impactful Education Through Innovative Engagement

roy.berger@theoncologyconsortium.com | (516) 729-0303

Julie Bauman, MD

Head and Neck Oncology Consortium

Dr. Julie Bauman is an Associate Professor of Medicine (Division of Hematology/Oncology) at the University of Pittsburgh Cancer Institute (UPCI), an NCI-designated Comprehensive Cancer Center. She was recruited in 2012 to serve as the Section Chief of Head and Neck Cancer (HNC), and Co-Leader of the UPMC HNC Center of Excellence. Dr. Baumann’s major goal is to design rigorous, biomarker-driven clinical trials to improve survival and survivorship in Head and Neck cancers.

Ezra Cohen, MD

Head and Neck Oncology Consortium

Ezra Cohen, MD is Professor of Medicine, UC San Diego Moores Cancer Center and Associate Director for Translational Science and team leader in Head and Neck Oncology as well as the Solid Tumor Therapeutics research program. He is an internationally renowned translational researcher, who has been acknowledged for his contribution to the National Cancer Institute Task Force on PI3 Kinase/AKT/mTOR Targeting. Among other roles, he chairs the Protocol Review and Monitoring Committee (PRMC) and serves as a member of the Cancer Council, C3 steering committee, and the cancer center’s Executive Committee. He was recently appointed as chair of the NCI Head and Neck Cancer Steering Committee that oversees NCI-funded clinical research (including all NCI Cooperative Group trials) in this disease.

Alan Ho, MD, PhD

Head and Neck Oncology Consortium

Alan L. Ho MD, PhD is a medical oncologist on the solid tumor service at Memorial Sloan Kettering Cancer Center. He did his undergraduate work at Washington University School of Medicine and Medical School at Stanford University, where he graduated Phi Beta Kappa. He did his Residency at Weill Cornell-NY Presbyterian and Fellowship at MSKCC. He specializes in the management of head and neck squamous cell carcinomas, thyroid cancers, salivary cancers, and non-melanoma skin cancers. His research is focused upon the translational science of developing novel therapeutics for these malignancies. He is the principal investigator (PI) of two NIH R01s and a co-PI in the MSK Thyroid Cancer Spore program. He is a member of the Experimental Therapeutics Committee in the Alliance for Clinical Trials in Oncology, and has served as the national PI of an NCI-cooperative group trial. Dr. Ho is currently the National Translational PI of the NCI MATCH clinical trial effort evaluating a hedgehog pathway inhibitor. He serves as a co-chair of the head and neck subsection of the International Clinical Trials in Rare Cancers Initiative and is a member of the National Comprehensive Cancer Network (NCCN) practice guidelines committee for the management of non-melanoma skin cancers. He is also the current chair of the MSK Investigational New Drug committee.

Lori Wirth, MD

Head and Neck Oncology Consortium

Dr. Wirth is the Medical Director of the Center for Head and Neck Cancer as Massachusetts General Hospital in Boston, and Assistant Professor at Harvard Medical School. She is the Secretary and Protocol Chair of the International Thyroid Oncology Group (ITOG), and will assume the Chairmanship of ITOG in May, 2015. Dr. Wirth is on NCCN’s Thyroid Cancer Committee and the NCI’s Head and Neck Cancer Recurrent/Metastatic Disease Task Force. Dr. Wirth’s research focuses on advanced thyroid cancer and clinical trials in squamous cell carcinoma of the head and neck.

Head and Neck Oncology Consortium

Download Capability Slide
Oncology Consortium | All Rights Reserved 2012-2017
Back to Top